AstraZeneca goes in vivo, penning $1B deal for Belgian off-the-shelf cell therapy biotech
AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all outstanding equity of the Belgian biotech for a total consideration of $1 billion—split between an upfront payment of $425 million and up to $575 million in developmental and regulatory milestones.
Partex's platform will provide comprehensive analyses, including target identification, indication expansion, and molecular profiling, ultimately accelerating the process of bringing innovative ...
Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...
There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.
Sutro Biopharma, a Bay Area oncology biotech company, is laying off around half its staff, switching up its leadership team ...
A new biotech is raising money to develop a drug believed to be capable of starving cancer cells, based on research out of a ...
Offering free solutions can generate goodwill and strengthen relationships with both existing and potential customers. When a ...
In this article, we will be taking a look at the 15 best biotech stocks to buy according to billionaires. Although biotech ...
Stocktwits on MSN11h
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last WeekThe clinical-stage biopharmaceutical company saw the highest jump in retail interest after reporting positive topline data ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share estimates for Legend Biotech in a ...
Investor's Business Daily on MSN2d
Stock Market Today: Dow Jones Gains 650 Points; This Biotech Name Pops 12% And Tops 3 IBD Lists (Live Coverage)The Dow Jones and S&P 500 posted robust gains Friday afternoon. Nvidia led the Dow and Ulta topped the S&P 500 on the stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback